These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 33413701)

  • 1. Identification and management of cardiometabolic risk in subjects with schizophrenia spectrum disorders: A Delphi expert consensus study.
    Galderisi S; De Hert M; Del Prato S; Fagiolini A; Gorwood P; Leucht S; Maggioni AP; Mucci A; Arango C
    Eur Psychiatry; 2021 Jan; 64(1):e7. PubMed ID: 33413701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delphi panel to obtain clinical consensus about using long-acting injectable antipsychotics to treat first-episode and early-phase schizophrenia: treatment goals and approaches to functional recovery.
    Arango C; Fagiolini A; Gorwood P; Kane JM; Diaz-Mendoza S; Sahota N; Correll CU
    BMC Psychiatry; 2023 Jun; 23(1):453. PubMed ID: 37344763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiometabolic health, prescribed antipsychotics and health-related quality of life in people with schizophrenia-spectrum disorders: a cross-sectional study.
    Bressington D; Mui J; Tse ML; Gray R; Cheung EF; Chien WT
    BMC Psychiatry; 2016 Nov; 16(1):411. PubMed ID: 27863522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC).
    De Hert M; Dekker JM; Wood D; Kahl KG; Holt RI; Möller HJ
    Eur Psychiatry; 2009 Sep; 24(6):412-24. PubMed ID: 19682863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group].
    Ames D; Camm J; Cook P; Falkai P; Gury C; Hurley R; Johnson G; Piepho R; Vieweg V;
    Encephale; 2002; 28(6 Pt 1):552-62. PubMed ID: 12506268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study.
    Correll CU; Robinson DG; Schooler NR; Brunette MF; Mueser KT; Rosenheck RA; Marcy P; Addington J; Estroff SE; Robinson J; Penn DL; Azrin S; Goldstein A; Severe J; Heinssen R; Kane JM
    JAMA Psychiatry; 2014 Dec; 71(12):1350-63. PubMed ID: 25321337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Consensus statements on adherence issues in schizophrenia for Hong Kong.
    Mak KY; Lo WT; Yeung WS; Wong M; Chung WS; Chui E; Tam KL; Hui LK; Mui J; Chan OW; Wong KL
    Asian J Psychiatr; 2014 Dec; 12():163-9. PubMed ID: 25440570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiometabolic health in people with HIV: expert consensus review.
    Batterham RL; Bedimo RJ; Diaz RS; Guaraldi G; Lo J; Martínez E; McComsey GA; Milinkovic A; Naito T; Noe S; O'Shea D; Paredes R; Schapiro JM; Sulkowski MS; Venter F; Waters L; Yoruk IU; Young B
    J Antimicrob Chemother; 2024 Jun; 79(6):1218-1233. PubMed ID: 38656584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delphi panel to obtain clinical consensus about using long-acting injectable antipsychotics to treat first-episode and early-phase schizophrenia: Treatment goals and approaches to functional recovery.
    Arango C; Fagiolini A; Gorwood P; Kane JM; Diaz-Mendoza S; Sahota N; Correll CU
    Res Sq; 2023 Mar; ():. PubMed ID: 36945577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antipsychotics Use Is Associated With Greater Adherence to Cardiometabolic Medications in Patients With Schizophrenia: Results From a Nationwide, Within-subject Design Study.
    Solmi M; Tiihonen J; Lähteenvuo M; Tanskanen A; Correll CU; Taipale H
    Schizophr Bull; 2022 Jan; 48(1):166-175. PubMed ID: 34286338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Place of the partial dopamine receptor agonist aripiprazole in the management of schizophrenia in adults: a Delphi consensus study.
    Llorca PM; Nuss P; Fakra É; Alamome I; Drapier D; El Hage W; Jardri R; Mouchabac S; Rabbani M; Simon N; Vacheron MN; Azorin JM
    BMC Psychiatry; 2022 May; 22(1):364. PubMed ID: 35643542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Which comes first: atypical antipsychotic treatment or cardiometabolic risk?
    Stahl SM; Mignon L; Meyer JM
    Acta Psychiatr Scand; 2009 Mar; 119(3):171-9. PubMed ID: 19178394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.
    Kane JM; Leucht S; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2003; 64 Suppl 12():5-19. PubMed ID: 14640142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment.
    Cooper SJ; Reynolds GP; ; Barnes T; England E; Haddad PM; Heald A; Holt R; Lingford-Hughes A; Osborn D; McGowan O; Patel MX; Paton C; Reid P; Shiers D; Smith J
    J Psychopharmacol; 2016 Aug; 30(8):717-48. PubMed ID: 27147592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delphi consensus on the physical health of patients with schizophrenia: evaluation of the recommendations of the Spanish Societies of Psychiatry and Biological Psychiatry by a panel of experts.
    Bobes-García J; Saiz-Ruiz J; Bernardo-Arroyo M; Caballero-Martínez F; Gilaberte-Asín I; Ciudad-Herrera A
    Actas Esp Psiquiatr; 2012; 40(3):114-28. PubMed ID: 22723130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of continuous glucose monitoring in diabetic patients at high cardiovascular risk: an expert-based multidisciplinary Delphi consensus.
    Di Mario C; Genovese S; Lanza GA; Mannucci E; Marenzi G; Sciatti E; Pitocco D;
    Cardiovasc Diabetol; 2022 Aug; 21(1):164. PubMed ID: 36030229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence and costs of cardiometabolic conditions in patients with schizophrenia treated with antipsychotic medications.
    Jerrell JM; McIntyre RS; Tripathi A
    Clin Schizophr Relat Psychoses; 2010 Oct; 4(3):161-8. PubMed ID: 20880826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses.
    Henderson DC; Vincenzi B; Andrea NV; Ulloa M; Copeland PM
    Lancet Psychiatry; 2015 May; 2(5):452-464. PubMed ID: 26360288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.